Aptose Biosciences Eulerpool News

Aptose Biosciences Aktie News

Aptose Biosciences wird von vielen Journalisten und Investoren weltweit beobachtet. Die aktuellsten Aptose Biosciences News stellen wir hier zusammen.

• 17. Juni ·

  Yahoo
  Aptose Provides Corporate Updates
• 12. Juni ·

  Yahoo
  Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
• 27. Mai ·

  Yahoo
  Aptose Announces Results from Annual and Special Meeting of Shareholders
• 23. April ·

  Yahoo
  Aptose Announces Auditor Not Standing for Re-Appointment
• 29. März ·

  Yahoo
  Aptose Biosciences price target raised to $6 from $2 at H.C. Wainwright
• 17. März ·

  Yahoo
  Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
• 12. Februar ·

  Yahoo
  Sector Update: Health Care Stocks Retreat Late Afternoon
• 9. Januar ·

  Yahoo
  Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
• 12. Dezember ·

  Yahoo
  Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax
• 3. Dezember ·

  Yahoo
  Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials